Distinguished in Pulmonary Embolism

Zhihong L. Liu

Beijing, CN 
Distinguished in Pulmonary Embolism
Beijing, CN 
OverviewLocationsClinical Research

Overview

Zhihong Liu practices in Beijing, China. Liu is rated as a Distinguished expert by MediFind in the treatment of Pulmonary Embolism. Their top areas of expertise are Pulmonary Hypertension, Hypertension, Pulmonary Embolism, Angioplasty, and Lung Transplant.

Their clinical research consists of co-authoring 134 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 30 articles in the study of Pulmonary Embolism.

Locations

Beijing, China
Other Locations
Chinese Academy Of Medical Sciences And Peking Union Medical College, No. 167, Beilishi Road, Beijing, Xicheng, 100037, China
Dalian, China
Shanghai, 200025, China
Fuzhou, 350025, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

An Open-Label Extension Trial to Evaluate the Safety of Continued Therapy With Subcutaneous Remodulin® in Subjects With Pulmonary Arterial Hypertension Who Completed Study CVT-CV-003
An Open-Label Extension Trial to Evaluate the Safety of Continued Therapy With Subcutaneous Remodulin® in Subjects With Pulmonary Arterial Hypertension Who Completed Study CVT-CV-003
Enrollment Status: Withdrawn
Publish Date: May 09, 2017
Intervention Type: Drug
Study Phase: Phase 4
A 16-Week, Open-Label, Multi-Center, Parallel, Randomized Controlled Study to Compare the Safety, Tolerability, Pharmacokinetics and Efficacy of Slow and Rapid Dose Titration Regimens of Subcutaneous Remodulin Therapy in Subjects With Pulmonary Arterial Hypertension
A 16-Week, Open-Label, Multi-Center, Parallel, Randomized Controlled Study to Compare the Safety, Tolerability, Pharmacokinetics and Efficacy of Slow and Rapid Dose Titration Regimens of Subcutaneous Remodulin Therapy in Subjects With Pulmonary Arterial Hypertension
Enrollment Status: Withdrawn
Publish Date: May 09, 2017
Intervention Type: Drug
Study Phase: Phase 4
View 1 Less Clinical Trial

134 Total Publications

Correction: Association of non-insulin-based insulin resistance indices with disease severity and adverse outcome in idiopathic pulmonary arterial hypertension: a multi-center cohort study.
Correction: Association of non-insulin-based insulin resistance indices with disease severity and adverse outcome in idiopathic pulmonary arterial hypertension: a multi-center cohort study.
Journal: Cardiovascular diabetology
Published: June 09, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Liu's expertise for a condition
ConditionClose
    View All 14 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile